Compare ATEN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEN | AUPH |
|---|---|---|
| Founded | 2004 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | 2014 | 2014 |
| Metric | ATEN | AUPH |
|---|---|---|
| Price | $30.09 | $15.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $26.33 | $17.25 |
| AVG Volume (30 Days) | 1.2M | ★ 1.2M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | 0.17 | ★ 0.25 |
| Revenue | $235,429,000.00 | ★ $283,055,000.00 |
| Revenue This Year | $13.02 | $17.54 |
| Revenue Next Year | $10.82 | $15.74 |
| P/E Ratio | $169.29 | ★ $60.72 |
| Revenue Growth | 2.36 | ★ 20.38 |
| 52 Week Low | $16.52 | $9.35 |
| 52 Week High | $38.49 | $19.25 |
| Indicator | ATEN | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 26.35 | 42.19 |
| Support Level | $17.00 | $14.60 |
| Resistance Level | $32.95 | $15.23 |
| Average True Range (ATR) | 1.54 | 0.55 |
| MACD | -0.98 | -0.09 |
| Stochastic Oscillator | 0.00 | 19.53 |
A10 Networks Inc is a provider of secure application and network infrastructure solutions for enterprises and service providers across on-premises, hybrid cloud, and distributed environments. The company's offerings include application delivery and traffic management, distributed denial-of-service (DDoS) protection, application and API security, and centralized management. It serves customers across multiple industries, including telecommunications, technology, financial services, public sector, industrial, retail, gaming, and education. The majority of the company's revenue is derived from the sale of secure networking and cybersecurity solutions and related maintenance and support services.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.